Skip to main content
TipRanks
Go Ultimate75% OFF

Idorsia Ltd (0RQE) Share Price & Analysis

5 Followers

0RQE Stock Chart & Stats

CHF 3.90CHF 0.03(0.78%)
At close: 4:30 PM GMT
CHF4CHF5CHF6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
CHF 3.87 - CHF 3.95
52-Week Range
CHF 2.82 - CHF 7.55
Previous Close
CHF 3.87
Volume
N/A
Average Volume (3M)
65.58K
Market Cap
CHF 1.06B
Enterprise Value
CHF 2.51B
Total Cash (Recent Filing)
CHF 85.10M
Total Debt (Recent Filing)
CHF 1.35B
Price to Earnings (P/E)
―
Beta
1.29
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Improving TTM revenue indicates that Idorsia is generating stronger commercial activity across its portfolio. If sustained, this growth can broaden the revenue base, improve absorption of fixed operating costs, and support greater financial contribution from existing and newly launched medicines.

High Gross Margin

The consistently high gross margin shows that Idorsia’s products can generate substantial value after direct costs. This provides economic capacity to fund research, commercialization, and partnering activity, although the benefit depends on reducing the much larger operating-cost burden.

Diversified Commercial Model

Combining direct product revenue with licensing, milestone, and royalty income gives Idorsia multiple ways to monetize its drug portfolio. This model can extend commercial reach through larger partners while preserving selected product economics and creating potential recurring royalty streams.

Bears Say

Negative Equity And High Leverage

Negative equity and debt materially above the company’s asset base indicate weak balance-sheet resilience. This limits financial flexibility, increases dependence on creditors or external funding, and can constrain Idorsia’s ability to invest consistently in its pipeline or absorb setbacks.

Persistent Cash Burn

Continuing negative operating and free cash flow means the business is not yet funding itself through operations. Although outflows improved versus 2022–2023, ongoing cash burn keeps funding risk elevated and may require additional financing before durable cash generation is achieved.

Deep Operating Losses

The very negative net margin and continued EBIT and EBITDA losses show that the current cost base remains far above revenue. This weak operating leverage reduces the immediate benefit of high gross margins and makes earnings recovery dependent on sustained growth and meaningful cost improvement.

Idorsia Ltd News

0RQE FAQ

What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest share price was CHF2.82 and its highest was CHF7.55 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.06B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 102 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Oct 29, 2026. The company reported -CHF0.17 earnings per share for the quarter, beating the consensus estimate of -CHF0.19 by CHF0.02.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.18.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,800,570 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.17 in its last earnings report, beating expectations of -CHF0.19. Following the earnings report the stock price went down -0.349%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in GB:0RQE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology